



PRESS RELEASE

## EDEN BIODESIGN ADVANCES TOWARD ESTABLISHING ITS U.S. OPERATION

### Michael Faughnan appointed as Business Development Director

**Liverpool, UK; 5 June 2008:** Eden Biodesign, one of the UK's leading contract bio manufacturers, announced today the appointment of Michael Faughnan as Business Development Director of its US subsidiary, Eden Biodesign, Inc. Michael will be supporting Dr. Roger Lias, President of Eden Biodesign, Inc. and Group Commercial Director, with the Company's expansion in the US and is responsible for North American Business Development activities.

Located in Southern California, Michael brings over 14 years of experience in successfully aiding clients in accelerating their biopharmaceutical products in to and through clinical development and to commercial launch.

Roger Lias welcomes the appointment of Michael Faughnan to the team: "Michael brings tremendous experience and will be an invaluable asset as we continue to build our US infrastructure and expand our services to clients in the North American market".

Most recently, Michael was Manager of Sales and Business Development at Cytovance Biologics, a contract manufacturing organization, where he was responsible for North American commercial activities including business development and marketing. Previously Michael spent five years as territory manager in the industrial cell culture media division of Irvine Scientific where he was instrumental in supporting numerous biotech industry leaders with media platform development. Prior to joining Irvine Scientific, Michael was a sales professional at Woodside Biomedical (now part of Abbott Laboratories).

"I am extremely excited to join such a strong team at Eden Biodesign" said Michael Faughnan. "Eden's high quality, flexible, EMEA inspected cGMP facilities and demonstrated expertise will help our customers to accelerate their products into clinical development and on to market. I am looking forward to introducing North American companies to Eden's broad biopharmaceutical service offering and to providing access to a depth of experience in the quality



and regulatory areas usually only available to major pharmaceutical companies."

## **Ends**

For further information contact:

Maria Patey, De Facto Communications Ltd  
+44 (0)20 7861 3838  
Email [m.patey@defacto.com](mailto:m.patey@defacto.com)

### **Notes to editors:**

#### **Eden Biodesign**

Eden Biodesign is a successful international biopharmaceutical development and manufacturing services business that provides 'state of the art' development and manufacturing services to biotech clients across Europe, the USA and Asia. It promises all clients a committed service plus the knowledge and expertise to guide clients through process development, manufacturing, regulatory and technology transfer challenges.

The company uses the principles of 'Good Science' at every step of biopharmaceutical development to design programmes and processes that deliver clinically and commercially valuable products, with an accomplished and attentive level of project management that clients need. For further information please visit [www.edenbiodesign.com](http://www.edenbiodesign.com).